研究单位：[1]BeiGene[2]Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology [3]Beijing Cancer Hospital[4]Peking Union Medical College Hospital
研究目的：
The primary objective of this study was to evaluate the efficacy of zanubrutinib in participants with centrally confirmed relapsed or refractory MCL.
